32 results about "Prediabetes" patented technology

The invention discloses a data-driven early-diabetic future diabetes-related disease progress risk prediction model and a construction method thereof, and the method comprises the steps: collecting clinical index data, including age, gender, BMI, WHR, HOMA-IR, HDL-C, TG, SBP, DBP, SCR and ALT, of early-diabetic patients in a training and verification queue; using an unsupervised soft clustering method combining dimension reduction based on UMAP, graph clustering and a Gaussian mixture model to identify the phenotypic heterogeneity of the prediabetes mellitus; obtaining the probability of the individual phenotype characteristics, evaluating the association between the probability and the development risk of the future diabetes related diseases in the early stage of diabetes, and constructing a development risk prediction model of the future diabetes related diseases in the early stage of urine diseases; and performing model optimization and robustness verification in the verification queue. According to the method, the heterogeneity of the prediabetes mellitus can be effectively identified, and accurate risk stratification and personalized prevention are realized.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

This invention relates to the intersection of traditional Chinese medicine modernization and intelligent healthcare, specifically falling under the category of pre-chronic disease screening and health management technology. More particularly, it relates to a method for diagnosing and treating pre-type 2 diabetes based on traditional Chinese medicine state theory, along with electronic devices and computer-readable storage media, constructing a complete, human-machine collaborative closed-loop diagnostic and treatment process. This method achieves objective data collection through portable devices using the four diagnostic methods of traditional Chinese medicine, utilizes a multi-algorithm fusion model to accurately identify the "potential pathological state" of pre-T2DM, and intelligently generates personalized intervention prescriptions based on this. Finally, it quantifies the effects and dynamically optimizes the treatment plan through data re-collection and model re-evaluation. This solves the problems of strong subjectivity in traditional Chinese medicine diagnosis and treatment, disconnection from modern technology, and lack of quantitative feedback and continuous adjustment after intervention. It achieves full-cycle, intelligent, and personalized health management for pre-T2DM, from identification and intervention to follow-up management.

Provided is a method and a system for noninvasive measurement of blood viscosity based on oxygen saturation and blood flow rate, which may easily and quickly calculate the blood viscosity by using the method and the system for noninvasive measurement of blood viscosity based on oxygen saturation and blood flow rate, thereby enabling immediate obtaining of the blood viscosity.

An AI-based system (100) designed to assess prediabetes risk in individuals. The system (100) integrates seamlessly with the user devices via rest APIs, ensuring secure communication through https. A data collection module (122) collects raw data forwards the data to standardization and pre-processing modules (124) for preparation. The pre-processed data is transmitted to the server (104) through a network (102) using an API integration module (126) and thereafter forwarded to the input module (112) that authenticates and validates patient data, which is transmitted to the processing module (114) that refines the data, while a prediction module (116) employs a deep learning model with an AUC of 0.87 to evaluate prediabetes risk. A clinical pathway (118) and risk prediction response (120) modules provide personalized protocols, risk status, and clinical recommendations. It (100) complements clinician decision-making, adheres to ISO 13485 standards, and serves as a cost-effective community-based prediabetes risk assessment.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

The invention discloses highly acetylated glucomannan and application thereof in preparation of a product with an effect of relieving prediabetes mellitus, and belongs to the technical field of medicines. In-vivo experiments prove that the glucomannan with high acetylation degree has the effect of relieving the prediabetic stage, which is specifically reflected in weight gain of mice in the prediabetic stage, regulation of blood glucose metabolism, improvement of glucose tolerance and insulin resistance, regulation of blood lipid metabolism, protection of liver and pancreatic tissues and reduction of epididymal fat cell size. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

The present invention pertains to a) beta-lactoglobulin or b) a nutritional composition comprising beta-lactoglobulin for use in preventing and / or treating a metabolic disorder and / or muscle atrophy. It also pertains to a method of preventing and / or treating a metabolic disorder and / or muscle atrophy in a subject. It furthermore pertains to use of a) beta-lactoglobulin or b) a nutritional composition comprising beta-lactoglobulin for increasing the level of insulin and / or glucagon in the blood of a subject and the present invention also pertains to a non-therapeutic use or method of a) beta-lactoglobulin orb) a nutritional composition comprising BLG. It also pertains to beta-lactoglobulin (BLG) for use in preventing and / or treating diabetes or prediabetes in a subject. It furthermore pertains to a nutritional composition for use in preventing and / or treating diabetes or prediabetes in a subject.

The present invention relates to a method for improving glucose homeostasis and / or lowering plasma glucose levels by administering a SIRT6 activator. The present invention also provides a method for treating hyperglycemia, prediabetes, and diabetes, including type I diabetes, type II diabetes, or gestational diabetes, by administering a SIRT6 activator.

The invention relates to a diabetes early subtype recognition and risk prediction system based on continuous blood glucose monitoring. The system comprises a data preprocessing module, a subtype recognition module, a physiological modeling module, a residual prediction module and a fusion prediction module. The data preprocessing module is used for interpolating and standardizing the continuous blood glucose monitoring data; the subtype recognition module is used for extracting a typical daily curve, performing clustering analysis and outputting a metabolic subtype tag; the physiological modeling module is used for constructing and fitting a glucose-insulin kinetic model and outputting personalized physiological parameters; the residual prediction module is used for training the LSTM network and predicting the residual of the dynamic model; and the fusion prediction module is used for dynamically fusing output of the two types of models and generating a final blood glucose prediction result. According to the method, subtypes of the early stage of diabetes can be recognized, a prediction analysis method with high precision and high interpretability can be provided for different subtypes, and individualized dynamic mode recognition and hybrid prediction based on continuous blood glucose monitoring (CGM) data are achieved.

A polymorphic form of a GLP-1R agonist compound (III), a preparation method therefor and a use thereof are provided. Compared with an amorphous form of compound (III), the polymorphic form has higher stability and better processability, and is more suitable for preparing a drug for preventing or treating diseases related to a GLP-1R target and a signaling pathway thereof, such as type 2 diabetes, prediabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, kidney disease, gout, hyperhematuria, cardiovascular disease, etc.

Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and / or biomarkers for diagnosing the disease are made possible.

According to the traditional Chinese medicine compound composition, rhizoma polygonati, radix codonopsis, rhizoma dioscoreae and fried rhizoma atractylodis macrocephalae are used as monarch medicines, and are used for replenishing qi and strengthening the spleen, and earthing up to build the middle energizer, so that transportation and transformation are right; poria cocos, coix seeds and radix fici simplicissimae are used as ministerial drugs, dried orange peel and fructus amomi are used as ministerial drugs, and the effects of dredging and regulating water channels, resolving dampness, enlivening the spleen, and promoting middle-jiao ascending and descending are achieved, so that three- Radix paeoniae alba, radix curcumae, fructus aurantii and radix cyathulae are matched with radix salviae miltiorrhizae as assistant medicines to soften the liver, dispel depression, regulate qi, guide stagnation, promote blood circulation and dredge collaterals, so that wood is prepared without lumbering, and collaterals are dredged without bitter cold; the radix scrophulariae and the radix ophiopogonis are used for nourishing yin, clearing and moistening, and strengthening yin without moistening greasy middle energizer so as to avoid dampness-aiding and spleen-trapping; and honey-fried licorice root and jujube are used as guide medicines to harmonize the medicines, regulate the middle warmer and protect the stomach so as to improve the symptoms of the diabetes mellitus in the early stage.

The invention belongs to the technical field of diabetes risk prediction, and provides a method and system for predicting the diabetes risk of children prediabetic population, and the method comprises the following steps: S1, multi-modal data fusion collection: collecting children clinical data, biochemical indexes, dynamic blood glucose monitoring data and type 1 diabetes specific data; s2, feature engineering and model construction: carrying out feature engineering processing on the collected data, and extracting key indexes; s3, model training: performing risk prediction by using a machine learning model, and outputting a risk level and a confidence coefficient; s4, generating a personalized intervention scheme according to the risk level; according to the method, the accuracy and reliability of prediction are remarkably improved by combining comprehensive analysis of multi-modal data, key indexes can be accurately extracted through feature engineering and model training, risk prediction can be carried out by utilizing a machine learning model, and the development of child prediabetic people into diabetic patients is effectively delayed or prevented.

The invention relates to a composition that can be used, in particular, as a food ingredient, food supplement, or medicinal product for the prevention of the risk of developing type 2 diabetes, said composition comprising a plant extract selected from each of the following plant families: - Fabaceae, - Lauraceae, - Cannabaceae, - Salicaceae. Figure 4

Provided herein are compositions composed of a plurality of minerals and vitamins that provide numerous health benefits and quality of life to subjects in need thereof. Also described herein are kits composed of the compositions described herein with a marine omega 3 fatty acid, coenzyme Q10, or a combination thereof. In one aspect, the compositions described herein can treat a subject diagnosed with prediabetes, type 1 diabetes, type 2 diabetes or insulin uptake. In another aspect, the compositions described herein can increase the performance of athletes by relaxing and dilating blood vessels, thus improve circulation as well as shorten the time of recovery after exercises or games. In another aspect, the compositions described herein can improve the well-being and immune response system. It also improves the human system against bacterial and fungal infections. In another aspect, the compositions described herein can treat myalgic encephalomyelitis in a subject. In another aspect, the compositions described herein can reduce or prevent one or more symptoms of Crohn's disease in a subject. In another aspect, the compositions described herein can enhance one or more physical properties of a subject after exercise.

This invention discloses a GLP-1R agonist, its synthesis method, and its uses, belonging to the pharmaceutical field. This invention provides a GLP-1R agonist with the structure shown in formula (I), which can be used to treat human GLP-1R-mediated diseases or conditions, such as type 2 diabetes, prediabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatosis, and cardiovascular diseases.

Aspects of the present disclosure include methods for treating a subject having a metabolic disorder by neuromodulation. Methods according to certain embodiments include applying electrical stimulation to the spinal cord of a subject (e.g., a subject diagnosed as having or determined to have diabetes or prediabetes) in a manner sufficient to treat at least one symptom of the metabolic disorder in the subject. In some embodiments, neuromodulation is sufficient to treat one or more symptoms of diabetes or prediabetes such as fasting plasma glucose concentration, non-fasting plasma glucose concentration, elevated hbA1c, glucose tolerance and insulin secretion by the subject. Systems having one or more electrodes configured for applying electrical stimulation to the spinal cord of the subject suitable for practicing the subject methods are also described.

The present invention relates to a synergistic herbal formulation comprising standardised extracts of Berbens aristata and Phyllanthus emblica for the management of elevated blood glucose levels, insulin resistance, prediabetes, and type 2 diabetes mellitus. The formulation includes Berberis aristata extract containing 1% to 30% berberine and a whole extract of Phyllanthus emblica comprising tannins, gallic acid, and ellagic acid. In preferred embodiments, lecithin is incorporated to enhance the bioavailability of berberine through phospholipid complexation. The invention also provides a scalable method for preparing the formulation using hydroalcoholic extraction and lyophilisation. The formulation demonstrates dual activity: reducing glucose levels and enhancing insulin sensitivity via PPAR-y modulation. Preclinical and clinical studies confirm its efficacy and safety. The formulation is suitable for oral administration in various dosage forms and offers a natural, steroid-free alternative to conventional antidiabetic agents. The invention further includes therapeutic kits and methods for treating metabolic disorders.

The present invention relates to a synergistic herbal formulation comprising standardised extracts of Berbens aristata and Phyllanthus emblica for the management of elevated blood glucose levels, insulin resistance, prediabetes, and type 2 diabetes mellitus. The formulation includes Berberis aristata extract containing 1% to 30% berberine and a whole extract of Phyllanthus emblica comprising tannins, gallic acid, and ellagic acid. In preferred embodiments, lecithin is incorporated to enhance the bioavailability of berberine through phospholipid complexation. The invention also provides a scalable method for preparing the formulation using hydroalcoholic extraction and lyophilisation. The formulation demonstrates dual activity: reducing glucose levels and enhancing insulin sensitivity via PPAR-y modulation. Preclinical and clinical studies confirm its efficacy and safety. The formulation is suitable for oral administration in various dosage forms and offers a natural, steroid-free alternative to conventional antidiabetic agents. The invention further includes therapeutic kits and methods for treating metabolic disorders.

The present disclosure relates to novel compounds comprising one or more aromatic boron-containing groups, including diborates, and methods of making the disclosed compounds. The present disclosure also relates to pharmaceutical compositions comprising the disclosed compounds, and their use in the prevention and treatment of diseases and disorders, such diseases and disorders include hyperglycemia, type 2 diabetes mellitus, impaired glucose tolerance, type 1 diabetes mellitus, obesity, metabolic syndrome X or dyslipidemia, gestational diabetes mellitus, prediabetes mellitus, Alzheimer's disease, MODY 1, MODY 2 or MODY 3 diabetes mellitus, mood disorders, and mental disorders.

The present disclosure relates to a computer-implemented method for determining the risk of developing diabetes in a feline, the method comprising the steps of: determining the risk of developing diabetes in the feline in order to assess whether the feline is likely to be pre-diabetic; and when the feline is determined to be pre-diabetic, determining the risk of developing diabetes in the feline within a time interval. The present disclosure also relates to a method for generating a machine learning system adapted to determine the risk of developing diabetes in a feline, and a computer-implemented system for determining the risk of developing diabetes in a feline.

This invention relates to the field of food processing technology and discloses a meal replacement powder composition with hypoglycemic activity and its preparation method. The meal replacement powder uses buckwheat flour, yam flour, bitter melon flour, konjac oligosaccharide, polygonatum powder, and hawthorn powder as raw materials, with an optimized ratio of 2.00g buckwheat flour, 1.00g yam flour, 0.50g bitter melon flour, 0.40g konjac oligosaccharide, 0.40g polygonatum powder, and 0.45g hawthorn powder. The preparation method includes raw material pretreatment and precise ingredient mixing steps. The meal replacement powder of this invention is rich in total polysaccharides, total flavonoids, and total phenolic active ingredients. Its in vitro α-glucosidase inhibition rate is similar to that of acarbose, and its α-amylase inhibition rate is superior to that of acarbose. With a GI value of 53.92 (low GI food), it can effectively delay the rise in postprandial blood glucose, meeting the blood sugar control needs of people with prediabetes. The process is simple, the raw materials are natural, and it has the potential for large-scale industrialization.

Aspects of the present disclosure are directed to methods and compositions for facilitating β-cell regeneration by inhibition of the HIF1α-PFKFB3 pathway. Certain aspects describe methods for treatment and prevention of prediabetes and diabetes, including type 2 diabetes. Also disclosed are methods and compositions for enhancing β-cell regeneration.

Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and / or biomarkers for diagnosing the disease are made possible.

The present invention relates to compositions comprising microorganisms for use in reducing blood urate concentration. These compositions can be used in the therapeutic and prophylactic treatment of subjects at risk of, or suffering from, elevated blood urate levels. The compositions can be pharmaceutical or nutraceutical compositions for the treatment and prevention of urate and hyperuricemia related diseases such as cardiovascular disease, metabolic syndrome, non-alcoholic fatty liver disease, chronic kidney disease, gout, insulin resistance, hypertension, dyslipidemia, renal insufficiency, obesity, prediabetes and diabetes.

A prediabetes detection system and method based on combination of electrocardiogram and electroencephalogram information are provided. The system includes: a signal obtaining module, configured to obtain an electrocardiogram signal and an electroencephalogram signal of a user in a noninvasive manner; a feature extraction module, configured to: perform dimension reduction processing on a combined feature set composed of an electrocardiogram feature and an electroencephalogram feature to obtain a plurality of dimension-reduced combined feature sets, and select an electrocardiogram feature and an electroencephalogram feature meeting a preset criteria of correlation by analyzing a correlation between the plurality of dimension-reduced combined feature sets and a blood glucose concentration value to constitute an optimized combined feature set; and a multimodal fusion module, configured to input the optimized combined feature set into a plurality of trained neural network models, to obtain a detection result by fusing results of the plurality of neural networks.

Aspects of the present disclosure include methods for treating at least one of insulin resistance, diabetes, and prediabetes, and, optionally, also non-alcoholic steatohepatitis (NASH). In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.

Aspects of the present disclosure are directed to methods and compositions for facilitating β-cell regeneration by inhibition of the HIF1α-PFKFB3 pathway. Certain aspects describe methods for treatment and prevention of prediabetes and diabetes, including type 2 diabetes. Also disclosed are methods and compositions for enhancing β-cell regeneration.